NCT02431845View on ClinicalTrials.gov

Pharmaco(Epi)Genetic, Proteomic, and Microbiomic Study of Obsessive-Compulsive Disorder

NARecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

January 1, 2013

Primary Completion Date

December 31, 2030

Study Completion Date

December 31, 2030

Conditions
Obsessive-Compulsive Disorder
Interventions
DRUG

SSRIs

usual dose SSRI for obsessive-compulsive disorder, i.e. fluoxetine 40\~80 mg dose equivalents

Trial Locations (1)

120-752

RECRUITING

Yonsei Univ. Health System Severance Hospital, Seoul

All Listed Sponsors
lead

Severance Hospital

OTHER